1044872-40-3

Basic information

• Product Name: 2-Amino-4,6-dichloro-nicotinicacidmethylester
• Synonyms: 2-Amino-4,6-dichloro-nicotinicacidmethylester;2-Amino-4,6-dichloropyridine-3-carboxylic acid methyl ester;Methyl 2-amino-4,6-dichloropyridine-3-carboxylate;Methyl 2-aMino-4,6-dichloronicotinate;3-Pyridinecarboxylicacid, 2-amino-4,6-dichloro-, methyl ester;2-amino-4,6-dichloro-, methyl ester
• CAS NO: 1044872-40-3
• Molecular Formula: C₇H₆Cl₂N₂O₂
• Molecular Weight: 221.04074
• EINECS: 1533716-785-6
• Mol File: 1044872-40-3.mol

Chemical Properties

• Boiling Point: 319.135 °C at 760 mmHg
• Flash Point: 146.808 °C
• Appearance: /
• Density: 1.506
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 2-Amino-4,6-dichloro-nicotinicacidmethylester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4,6-dichloro-nicotinicacidmethylester(1044872-40-3)
• EPA Substance Registry System: 2-Amino-4,6-dichloro-nicotinicacidmethylester(1044872-40-3)

Safety Data

• Hazardous Substances Data: 1044872-40-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-4,6-dichloro-nicotinicacidmethylester is used as an intermediate in the synthesis of macrocyclic broad-spectrum antibiotics. These antibiotics are designed to target a wide range of bacterial infections, making them valuable in treating various diseases caused by different types of bacteria.
Used in Agrochemical Industry:
Although not explicitly mentioned in the provided materials, 2-Amino-4,6-dichloro-nicotinicacidmethylester may also have potential applications in the agrochemical industry. Given its structural features, it could be used as a precursor in the development of new pesticides or herbicides, contributing to more effective and targeted crop protection strategies.

Upstream product

• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 420-04-2 CYANAMID 
• 523992-26-9 methyl 2-amino-4,6-dihydroxypyridine-3-carboxylate 

Downstream Products

• 1262132-81-9 2-({[7-hydroxy-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]carbonyl}amino)acetic acid 
• 1262133-52-7 C₁₆H₁₄ClN₃O₂ 
• 1262133-53-8 7-chloro-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylic acid 
• 1262133-54-9 methyl 2-({[7-chloro-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]carbonyl}amino)acetate 
• 1253732-89-6 2-[4-(2-aminoethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-3H-pyrido[2,3-d]pyrimidin-4-one 
• 1253732-84-1 N-{2-[4-(5,7-dimethoxy-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2,6-dimethylphenoxy]ethyl}acetamide 
• 1253733-03-7 N-[4-(5,7-dimethoxy-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2,6-dimethylbenzyl]acetamide 
• 1044871-12-6 2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one 
• 1044871-00-2 2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-5,7-dimethoxy-3H-pyrido[2,3-d]pyrimidin-4-one 
• 1044870-97-4 2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one 

Relevant articles and documents

METHOD FOR PRODUCING TRIAZOLOPYRIDINE COMPOUND

The present invention relates to a novel method for producing a triazolopyridine compound or a salt thereof having a PHD inhibitory action and useful for treating or preventing diseases caused by decreased production of EPO, or the like. The present invention provides a method for producing 2-({[7-hydroxy-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]carbonyl}amino)acetic acid comprising a step of reacting Compound [VI]: wherein R61, R62 and R111 are as defined in the specification, or a salt thereof.

TYK2 INHIBITORS AND USES THEREOF

Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

COMPOUNDS AND METHODS OF USE

This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.

TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT

The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

NOVEL ANTI-INFLAMMATORY AGENTS

Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.